The GRPR antagonist 177Lu RM2 has been evaluated in mCRPC patients with high uptake in prostate cancer cells and demonstrates rapid clearance from physiologic GRPR expressing tissues, such as the pancreas [67]. This evidence concerns the gene GRPR and prostate cancer.